{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:56:58Z","timestamp":1694570218372},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s11897-004-0008-5","type":"journal-article","created":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T10:58:38Z","timestamp":1187521118000},"page":"190-196","source":"Crossref","is-referenced-by-count":5,"title":["Vasopressin antagonists in heart failure"],"prefix":"10.1007","volume":"1","author":[{"given":"Ladan","family":"Golestaneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Talreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry H.","family":"Le Jemtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","volume":"341","author":"R Schrier","year":"1999","unstructured":"Schrier R, Abraham W: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577\u2013585.","journal-title":"N Engl J Med"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","volume":"106","author":"B Kramer","year":"1999","unstructured":"Kramer B, Schweda F, Riegger G, et al.: Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999, 106:90\u201396.","journal-title":"Am J Med"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","volume":"147","author":"J Butler","year":"2004","unstructured":"Butler J, Forman D, Abraham W, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331\u2013338.","journal-title":"Am Heart J"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(02)00244-4","volume":"54","author":"M Naitoh","year":"2002","unstructured":"Naitoh M, Risvanis J, Balding LC, et al.: Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V (1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res 2002, 54:13\u201315.","journal-title":"Cardiovasc Res"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","volume":"5","author":"S Goldsmith","year":"1999","unstructured":"GoldsmithS: Vasopressin: a therapeutic target in congestive heart failure. J Card Fail 1999, 5:347\u2013356.","journal-title":"J Card Fail"},{"key":"8_CR6","first-page":"601","volume-title":"Cardiovascular Pharmacotherapeutics","author":"W Frishman","year":"2003","unstructured":"Frishman W, Klaphotz M, Acharya N, Mayerson A: Vasopressin and vasopressin-receptor antagonists in the treatment of cardiovascular disease. In Cardiovascular Pharmacotherapeutics, edn 2. Edited by Frishman WH, Sonnenblick EH, Sica DA. New York: McGraw-Hill; 2003:601\u2013616.","edition":"edn 2"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","volume":"146","author":"C Lee","year":"2003","unstructured":"Lee C, Watkins M, Patterson H, et al.: Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003, 146:9\u201318.","journal-title":"Am Heart J"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00129784-200303010-00002","volume":"3","author":"S Russell","year":"2003","unstructured":"Russell S, DeWald T: Vasopressin receptor antagonists: therapeutic potential in management of chronic heart failure. Am J Cardiovasc Drugs 2003, 3:13\u201320.","journal-title":"Am J Cardiovasc Drugs"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1681\/ASN.V133798","volume":"13","author":"C Wilcox","year":"2002","unstructured":"WilcoxC: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:798\u2013805.","journal-title":"J Am Soc Nephrol"},{"key":"8_CR10","first-page":"197","volume":"6","author":"DC Barter","year":"2000","unstructured":"BarterDC: Diuretic response in congestive heart failure. Congest Heart Fail 2000, 6:197\u2013201.","journal-title":"Congest Heart Fail"},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/pmj.79.931.268","volume":"79","author":"LKM Bruyne","year":"2003","unstructured":"BruyneLKM: Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 2003, 79:268\u2013271.","journal-title":"Postgrad Med J"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2003.10.003","volume":"147","author":"P Lapman","year":"2004","unstructured":"Lapman P, Golduber G, LeJemtel T: Heart failure treatment and renal function. Am Heart J 2004, 147:331\u2013338.","journal-title":"Am Heart J"},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","volume":"284","author":"SS Shanker","year":"2003","unstructured":"Shanker SS, Brater DC: Loop diuretics from Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003, 284:F11-F21.","journal-title":"Am J Physiol Renal Physiol"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mhj.2002.123144","volume":"144","author":"G Neuberg","year":"2002","unstructured":"Neuberg G, Miller A, O\u2019Connor C: Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002, 144:31\u201338.","journal-title":"Am Heart J"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B et al.: Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003, 42:705\u2013708.","journal-title":"J Am Coll Cardiol"},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","volume":"100","author":"H Cooper","year":"1999","unstructured":"Cooper H, Dries D, Davis CE, et al.: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311\u20131315.","journal-title":"Circulation"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"SR Goldsmith","year":"1983","unstructured":"Goldsmith SR, Francis GS, Cowley AW, et al.: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983, 1:1385\u20131390.","journal-title":"J Am Coll Cardiol"},{"key":"8_CR18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.V103647","volume":"10","author":"S Nielsen","year":"1999","unstructured":"Nielsen S, Kwon T, Christensen B, et al.: Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999, 10:647\u2013663.","journal-title":"J Am Soc Nephrol"},{"key":"8_CR19","doi-asserted-by":"crossref","unstructured":"Hasler U, Mordasini D, Bens M, et al.: Long term regulation of aquaporin-2 expression in vasopressin responsive renal collecting duct principal cell. J Biol Chem 277:10379\u201310388.","DOI":"10.1074\/jbc.M111880200"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","volume":"124","author":"AL Gerbes","year":"2003","unstructured":"Gerbes AL, Gulberg V, Gines P, et al.: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933\u2013939.","journal-title":"Gastroenterology"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","volume":"37","author":"F Wong","year":"2003","unstructured":"Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremis: a multicenter, randomized, placebo-controlled trial. Hepatology 2003, 37:182\u2013191.","journal-title":"Hepatology"},{"key":"8_CR22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9343(01)00678-7","volume":"110","author":"G Decaux","year":"2001","unstructured":"DecauxG: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001, 110:582\u2013584.","journal-title":"Am J Med"},{"key":"8_CR23","first-page":"H2245","volume":"267","author":"M Naitoh","year":"1994","unstructured":"Naitoh M, Suzuki H, Murakami M, et al.: Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994, 267:H2245-H2254.","journal-title":"Am J Physiol"},{"key":"8_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1043661802002062","volume":"46","author":"T Yatsu","year":"2002","unstructured":"Yatsu T, Kusayama T, Tomura Y, et al.: Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetized dogs. Pharmacol Res 2002, 46:371\u2013373.","journal-title":"Pharmacol Res"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(02)02101-5","volume":"450","author":"K Wada","year":"2002","unstructured":"Wada K, Tahara A, Arai Y, et al.: Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 2002, 450:169\u2013177.","journal-title":"Eur J Pharmacol"},{"key":"8_CR26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0002-9149(85)90743-X","volume":"55","author":"P Nicod","year":"1985","unstructured":"Nicod P, Waeber B, Bussien JP, et al.: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985, 55:1043\u20131047.","journal-title":"Am J Cardiol"},{"key":"8_CR27","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"J Udelson","year":"2001","unstructured":"Udelson J, Smith W, Hendrix G, et al.: Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417\u20132423.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"8_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0735-1097(02)80688-X","volume":"39","author":"J Udelson","year":"2002","unstructured":"Udelson J, Orlandi C, O\u2019Brien T, et al.: Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002, 39(Suppl 1):156. Combined V2\/V1a antagonism holds promise. The V2 antagonist effects are more apparent and the V1a effects are more difficult to interpret but hold promise, if demonstrable in further studies.","journal-title":"J Am Coll Cardiol"},{"key":"8_CR29","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1071-9164(03)00234-3","volume":"9","author":"J Burnett","year":"2003","unstructured":"Burnett J, Smith W, Ouyang J: Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy [abstract]. J Card Fail 2003, 9:S12.","journal-title":"J Card Fail"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 2003, 107:2690\u20132696.","journal-title":"Circulation"},{"key":"8_CR31","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis W, O\u2019Connor C, et al.: Effect of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA 2004, 291:1963\u20131971. In this study, selective V2 antagonism achieved aquaresis as evidenced by sustained increased sodium, decreased urine osmolality, and increased urine output.","journal-title":"JAMA"},{"key":"8_CR32","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1681\/ASN.V10102165","volume":"10","author":"P Martin","year":"1999","unstructured":"Martin P, Abraham W, Lieming A, et al.: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999, 10:2165\u20132170.","journal-title":"J Am Soc Nephrol"},{"key":"8_CR33","first-page":"839","volume":"171A","author":"M Gheorghiade","year":"2002","unstructured":"Gheorghiade M, Konstam M, Udelson J, et al.: Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients [abstract]. J Am Coll Cardiol 2002, 171A:839\u2013841.","journal-title":"J Am Coll Cardiol"},{"key":"8_CR34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1067\/mhj.2003.39","volume":"145","author":"S Russell","year":"2003","unstructured":"Russell S, Selaru P, Pyne D, et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose Evaluation of a Vasopressin Antagonist in CHF Patients Undergoing Exercise) trial. Am Heart J 2003, 145:179\u2013186.","journal-title":"Am Heart J"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-004-0008-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-004-0008-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-004-0008-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T01:28:30Z","timestamp":1629595710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-004-0008-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11897-004-0008-5","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}